-
EP3501502
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3501502
| EP3501502 - FIXED DOSED PHARMACEUTICAL COMPOSITIONS COMPRISING AMLODIPINE, RAMIPRIL AND ATORVASTATIN [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 10.07.2020 Database last updated on 31.08.2024 | |
| Former | The application has been published Status updated on 24.05.2019 | Most recent event Tooltip | 10.07.2020 | Application deemed to be withdrawn | published on 12.08.2020 [2020/33] | Applicant(s) | For all designated states Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim / DE | [2019/26] | Inventor(s) | 01 /
KAHM, Andreas Mühlstraße 88 D-55218 Ingelheim / DE | 02 /
JÜNEMANN, Daniel Markt 1d D-65346 Eltville / DE | [2019/26] | Representative(s) | Drescher, Christian Stauferring 36 55218 Ingelheim am Rhein / DE | [2019/26] | Application number, filing date | 17208852.8 | 20.12.2017 | [2019/26] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3501502 | Date: | 26.06.2019 | Language: | EN | [2019/26] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 16.02.2018 | Classification | IPC: | A61K9/20, A61K9/24, A61K31/40, A61K31/4422 | [2019/26] | CPC: |
A61K9/209 (EP);
A61K31/40 (EP);
A61K31/403 (EP);
A61K31/4422 (EP);
A61K9/2077 (EP)
| C-Set: |
A61K31/403, A61K2300/00 (EP);
A61K31/40, A61K2300/00 (EP);
A61K31/4422, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/26] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | FEST DOSIERTE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT AMLODIPIN, RAMIPRIL UND ATORVASTATIN | [2019/26] | English: | FIXED DOSED PHARMACEUTICAL COMPOSITIONS COMPRISING AMLODIPINE, RAMIPRIL AND ATORVASTATIN | [2019/26] | French: | COMPOSITIONS PHARMACEUTIQUES DOSÉES FIXES COMPRENANT DE L'AMLODIPINE, DU RAMIPRIL ET DE L'ATORVASTATINE | [2019/26] | Examination procedure | 03.01.2020 | Application deemed to be withdrawn, date of legal effect [2020/33] | 29.01.2020 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2020/33] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.12.2019 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]EP2070520 (LEK PHARMACEUTICALS [SI]) [Y] 1-15 * example - *; | [XY]CN101612403 (LIYAN WANG) [X] 1-7,10,11,13,14 * example 4 * [Y] 1-15; | [Y]WO2011104588 (SANOFI AVENTIS DEUTSCHLAND [DE], et al) [Y] 1-15 * example - *; | [Y]WO2015022559 (EGIS GYÓGYSZERGYÁR ZRT [HU]) [Y] 1-15 * example - *; | [Y] - LANATI EP ET AL, "Budget Impact Analysis of Triveram for The Treatment of Hypertension in Italy", VALUE IN HEALTH, (20160101), vol. 19, no. 7, doi:10.1016/J.JVAL.2016.09.1709, ISSN 1098-3015, XP029798526 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.jval.2016.09.1709 | [Y] - HUFFMAN MARK D ET AL, "Uses of polypills for cardiovascular disease and evidence to date", THE LANCET, THE LANCET PUBLISHING GROUP, GB, (20170310), vol. 389, no. 10073, doi:10.1016/S0140-6736(17)30553-6, ISSN 0140-6736, pages 1055 - 1065, XP029937678 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/S0140-6736(17)30553-6 | by applicant | EP0079022 | EP0244944 | WO9703959 | CN101612403 |